(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 January 2013 (17.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/007381 A1

(51) International Patent Classification:
A61K 9/10 (2006.01) *A61K 9/00* (2006.01)
A61K 9/107 (2006.01) *A61K 31/473* (2006.01)
A61K 9/08 (2006.01) *A61P 25/16* (2006.01)

(21) International Application Number:
PCT/EP2012/002916

(22) International Filing Date:
11 July 2012 (11.07.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11290320.8 11 July 2011 (11.07.2011) EP

(71) Applicant *(for all designated States except US)*: **BRITANNIA PHARMACEUTICALS LTD.** [GB/GB]; 65 London Road, Newbury, Berkshire, RG14 1JN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DEY, Michael** [GB/GB]; 40 Park Lane, Sandbach, Cheshire, CW11 1EW (GB). **RICHARD, Joel** [FR/FR]; 1 rue Saint-Blaise, F-78490 Méré (FR). **BARONNET, Marie-Madeleine** [FR/FR]; 18 rue Clovis Vigny, F-27530 Ezy sur Eure (FR). **MONDOLY, Nathalie** [FR/FR]; 5 square Raphael, F-78150 Le Chesnay (FR). **BERTOCCHI, Laurent** [FR/FR]; 1 chemin du Bois de Louvines - La Millerette, F-27240 Sylvains les Moulins (FR). **HARNETT, Jeremiah** [IE/FR]; 32 allée de la Bergerie, F-91190 Gif-sur-Yvette (FR).

(74) Agent: **MÜNCH, Konrad J.**; Kernebeck Patentanwalts Gmbh, Stiftstrasse 2, 60313 Frankfurt on the Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: A NEW THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT




Figure 1

(57) **Abstract**: The present invention relates to a pharmaceutical composition containing apomorphine as the active pharmaceutical ingredient, co-solvent, antioxidant, water having a pH greater than 4. The pharmaceutical formulation is suitable for parenteral administration for the treatment of Parkinson's disease

WO 2013/007381 A1